Charles River Laboratories International, Inc. (CRL) reported third-quarter 2024 adjusted earnings per share (EPS) of $2.59, which declined 4.8% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 6.6%.On a GAAP basis, earnings declined 21.3% year over year to $1.33 per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.RevenuesRevenues totaled $1.01 billion, beating the Zacks Consensus Estimate by 3.4%. However, the top line declined 1.6% from the year ...

Charles River Laboratories (CRL) reported $1.01 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 1.6%. EPS of $2.59 for the same period compares to $2.72 a year ago.The reported revenue represents a surprise of +3.33% over the Zacks Consensus Estimate of $977.22 million. With the consensus EPS estimate being $2.43, the EPS surprise was +6.58%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.58%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.39 per share when it actually produced earnings of $2.80, delivering a surprise o ...

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES THIRD-QUARTER 2024 RESULTS – Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – WILMINGTON, MA, November 6, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 202 ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Charles River Laboratories (CRL) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers ar ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Charles River Laboratories (CRL) , which belongs to the Zacks Medical Services industry. This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 13.94%. For the last reported quarter, Charles River came ou ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report third-quarter 2024 results on Nov. 6, before market open.In the last reported quarter, the company’s adjusted earnings per share of $2.80 surpassed the Zacks Consensus Estimate by 17.2%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.64%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.CRL’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged ...

PHILADELPHIA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing enabling technology, and Charles River Laboratories (Charles River), a global industryleading drug discovery, preclinical development, manufacturing and testing solutions provider, today announced a collaboration to demonstrate the benefits of Ori's next-generation CGT manufacturing platform, IRO®(eeRO). In early 2024, Ori and Charles River collaborated through Ori's LightSpeed Early Acc ...

Charles River Laboratories International, Inc. (CRL) and Insightec announced a five-year strategic collaboration to advance the applications of focused ultrasound (FUS) for drug discovery and preclinical development of therapeutics in neuroscience. Under the partnership, Charles River's clients will gain access to Insightec's novel low-frequency ultrasound platform, which non-invasively disrupts the blood-brain barrier, enabling drugs to be delivered to targeted brain areas. The latest development is expect ...

It has been about a month since the last earnings report for Charles River Laboratories (CRL) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Charles River due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Charles River Q2 Earnings Bea ...